Study: Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine
14 Sep, 2017 | 20:45h | UTCFinal efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial – The Lancet (link to abstract – $ for full-text)
Commentary: Vaccine to prevent most cervical cancers shows long-term effectiveness – eCancer News (free)